Friday, 21 December 2012

Alzheimer's disease treated by blocking immune response

Researchers from the German Center for Neurodegenerative Diseases, DZNE, as well as the University of Bonn, have discovered that the protein complex NLRP3 is a critical factor in the development of Alzheimer's disease.

The researchers studied the complex "NLRP3 inflammasome" which is already known to have a very important role in the immune system. Its activation means that immune cells are mobilised and inflammation-causing substances can be released.

Alzheimer's disease occurs when plaques begin forming in the brain, which then activate the NLRP3 inflammasome. The researchers in this study looked at the effects that its increased activity has on the brain.

Prof. Michael Heneka and his team studied the brains of dead Alzheimer's patients and mice with disorders that are related to Alzheimer's disease. It was found that the NLRP3 was active in both the humans and the mice. The researchers believed that by suppressing the inflammatory reactions of the protein complex there would be a reduction in the damaging plaques. They then removed the genes that activates NLRP3 inflammasome activity in another group of mice, which meant they were no longer able to synthesise the protein complex. The result of this was that they only showed mild symptoms of Alzheimer's-associated disorders.

This research could result in pharmaceuticals being developed to target the protein complex and inhibit its activity, and the team are already looking for potential ways to block the inflammasome. Prof. Heneka commented: "The testing of potential substances in the laboratory would be a next step. We hope to start as early as next year."

Jack

No comments:

Post a Comment